Work

P2.08-05 IMRPrinter: A Phase 1/1b Trial of IMU-201 (PD1-Vaxx) as Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.572

Authors: M. Boyer, M. Gutierrez, J. Park, G. Richardson, P. Savvides, L. Chong, N. Ede, Y. Kim, U. McCurry, S. Yavrom, G. Selvaggi, D. Carbone

Institutions: Chris O’Brien Lifehouse, Hackensack University Medical Center, Macquarie University, Cabrini Hospital, Mayo Clinic Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045420

FWCI:

Cites:

Cited by:

Related to: 10